Abstract

Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability?

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Understanding the Preferences of Patients and Caregivers for Relapsed/Refractory Multiple Myeloma Treatment: A Mixed-Mode Patient-Centric Approach
Daniel Auclair ... Joseph Mikhael
Blood | VOL. 130
Daniel Auclair, et. al.Daniel Auclair ... Joseph Mikhael
25 Jun 2021
Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study
...
Blood | VOL. 138
, et. al. ...
05 Nov 2021
Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma
Ajai Chari ...
Blood | VOL. 138
Ajai Chari, et. al.Ajai Chari ...
05 Nov 2021
Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma
...
Blood | VOL. 136
, et. al. ...
05 Nov 2020
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Momelotinib for the treatment of myelofibrosis.
Prithviraj Bose
Blood | VOL. -
Prithviraj BosePrithviraj Bose
03 Jul 2024
Efficacy of T cell assays for the diagnosis of primary defects in cytotoxic lymphocyte exocytosis.
Samuel C.C Chiang ... Yenan T Bryceson
Blood | VOL. -
Samuel C.C Chiang, et. al.Samuel C.C Chiang ... Yenan T Bryceson
03 Jul 2024
Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications.
Elsa Bernard ... Elli Papaemmanuil
Blood | VOL. -
Elsa Bernard, et. al.Elsa Bernard ... Elli Papaemmanuil
03 Jul 2024
Eltrombopag plus diacerein vs. eltrombopag in patients with ITP: a multicenter, randomized, open-label, phase 2 trial.
Lu Sun ... Yu Hou
Blood | VOL. -
Lu Sun, et. al.Lu Sun ... Yu Hou
03 Jul 2024
View more papers